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Abstract Cancer is a clonal evolutionary process, caused by successive accumulation of genetic 
alterations providing milestones of tumor initiation, progression, dissemination, and/or resistance  
to certain therapeutic regimes. To unravel these milestones we propose a framework, tumor 
evolutionary directed graphs (TEDG), which is able to characterize the history of genetic alterations 
by integrating longitudinal and cross-sectional genomic data. We applied TEDG to a chronic 
lymphocytic leukemia (CLL) cohort of 70 patients spanning 12 years and show that: (a) the evolution 
of CLL follows a time-ordered process represented as a global flow in TEDG that proceeds from 
initiating events to late events; (b) there are two distinct and mutually exclusive evolutionary paths 
of CLL evolution; (c) higher fitness clones are present in later stages of the disease, indicating a 
progressive clonal replacement with more aggressive clones. Our results suggest that TEDG may 
constitute an effective framework to recapitulate the evolutionary history of tumors.
DOI: 10.7554/eLife.02869.001
Introduction
Cancer is a complex, Darwinian, adaptive clonal evolutionary process, driven by the accumulation of 
genetic alterations that confer high proliferative and survival advantage (Merlo et al., 2006; Greaves 
and Maley, 2012). Recent advances in sequencing technologies have allowed uncovering the most 
common genetic alterations of many tumors, but the temporal order of most of these alterations is still 
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unknown (Futreal et al., 2004; Greenman et al., 2007; Santarius et al., 2010; Lawrence et al., 
2014). Temporal patterns of genetic alterations may indicate the fate of tumor progression, allowing 
early diagnosis of tumor subtypes and improving the choice of therapeutic strategies.
To understand the evolutionary history of tumors, several experimental and computational strate-
gies have been used. Longitudinal strategies require samples at multiple time points spanning the 
clonal tumor evolution process (Fearon and Vogelstein, 1990; Campbell et al., 2010; Ding et al., 
2010; Notta et al., 2011; Gerlinger et al., 2012; Turajlic et al., 2012; Landau et al., 2013). Landau 
et al. sampled leukemia cells from 18 CLL patients at two time points, revealing that SF3B1 and 
TP53 mutations are late events in subclonal tumor cells (Landau et al., 2013). The study of different 
stages of colorectal carcinogenesis showed the sequence of genetic events to be APC, KRAS, and 
then TP53 (Fearon and Vogelstein, 1990). Another alternative approach is a cross-sectional strategy, 
which makes use of a large cohort of patients to computationally predict the preferred orders. RESIC 
is a stochastic process model to identify the order of mutations (Attolini et al., 2010), which success-
fully confirmed the results in colorectal cancer, suggesting that cross-sectional data is informative for 
the prediction of mutation order. However, RESIC does not consider a critical aspect of carcinogenesis 
that most tumors are heterogeneous (Parsons, 2011).
Following the assumption that different tumors proceed through related temporally ordered altera-
tions, we propose to summarize tumor histories using a newly developed analytical approach that 
integrates the genomic information from different longitudinally characterized patients. Our method, 
termed tumor evolutionary directed graphs (TEDG), proceeds in two steps to ensemble in a simplified 
way cancer clonal evolutionary histories of large number of patients: first, by merging the evolutionary 
history of each patient, and second, by removing indirect relationships using spectral techniques for 
network deconvolution (Feizi et al., 2013). The resulting TEDG is a directed graph with nodes repre-
senting driver genes and arrows representing temporal order of gene lesions. A non-randomly distrib-
uted TEDG shows that cancer proceeds in an orchestrated fashion and indicates the main paths and 
the alternative routes of cancer evolution.
eLife digest A historical event is often the culmination of the preceding circumstances. The 
same can be said of cancer as a disease. Cancer results from genetic mutations that disrupt the 
normal biological processes within a cell, removing the fail-safes that prevent it from growing and 
reproducing uncontrollably.
Cancer is not caused by just one mutation, and once one gene is malfunctioning, other genes 
become much more likely to mutate. Although modern sequencing methods have revealed many of 
the genes that mutate in several different kinds of cancer, uncovering when each of these mutations 
occurs has been more difficult. Knowing when each mutation occurs could make it easier to predict 
how the cancer will progress and could also help target cancer treatments more effectively.
Wang, Khiabanian, Rossi et al. have devised a new method of studying the history of genetic 
mutations of cancer patients. This combines a ‘longitudinal’ method that looks at how mutations 
develop in a single tumor by taking samples from it at different times and ‘cross-sectional’ methods 
that make predictions based on data collected from a large number of patients. Wang, Khiabanian, 
Rossi et al. call this method ‘tumor evolutionary directed graphs’ (TEDG), as it produces a graph 
that shows how different gene mutations are related to each other. Initial tests showed that the 
TEDG method could accurately decipher the main chain of events in cancer evolution when used on 
data collected from at least 30 patients.
Wang, Khiabanian, Rossi et al. then used TEDG on data from 164 tumor samples collected over 
12 years from 70 patients with chronic lymphocytic leukemia, the type of leukemia that is most 
widespread amongst adults in Western countries. This uncovered two separate ways that this 
cancer may develop, one of which has a higher risk of life-threatening complications.
Knowing which of the two ways chronic lymphocytic leukemia is progressing in a patient could 
help treat the disease, as each pathway responds differently to different treatments. In addition, 
understanding the paths that cancer progression follows could also provide early warning signals of 
the mutations that will occur next. This could help to develop alternative, targeted cancer treatments.
DOI: 10.7554/eLife.02869.002
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In this study, we have applied TEDG to study the dynamics of the acquisition of alterations in 
chronic lymphocytic leukemia (CLL), which represents the most common adult leukemia in Western 
countries (Hallek et al., 2008; Müller-Hermelink et al., 2008). CLL is an ideal model for studying 
clonal dynamics because it is possible to collect highly purified sequential samples over time, and its 
clinical course is well characterized by serial cycles of response, remissions, and relapse ending in some 
instances with the development of lethal complications such as chemoresistant progression or trans-
formation into an aggressive lymphoma (Richter syndrome) (Pasqualucci et al., 2011; Zenz et al., 
2012; Fabbri et al., 2013). No systematic approach has been followed to disentangle and charac-
terize the ensemble of evolutionary histories of this disease. For this purpose, we envision a dual 
cross-sectional and longitudinal strategy by collecting genomic information from the most common 
alterations in a cohort of 70 CLL patients spanning over a period of 12 years (2001–2012).
Results
Tumor Evolutionary Directed Graphs
To recapitulate and compare the history of genetic alterations in many patients, we propose a frame-
work to infer TEDG by integrating longitudinal and cross-sectional genomic data of cancer patients. 
First, we reconstruct the sequential network of genetic alterations in each patient by analyzing genomic 
data from different time points. Specifically, the techniques of high-depth next generation sequencing 
(NGS) and fluorescence in situ hybridization (FISH) are separately carried out to assess the mutation 
allele frequency (MAF) and copy number abnormalities (CNA) of selected driver genes. To unify both 
types of data, and to adjust the MAF of mutations in genes with CNA, we introduce mutation cell 
frequency (MCF, defined as the fraction of tumor cells with a particular alteration) for quantification 
of genetic lesions (‘Materials and methods’, Figure 1—figure supplement 1). Based on MCF, we 
investigate alterations represented in at least 5% of leukemic cells (see examples of CLL patients in 
Figure 1—figure supplement 2). First, if a given genetic lesion is observed to be temporally earlier 
than another lesion, we connect them with a directed edge to represent their sequential order of 
development (Figure 1A). Second, we pool many sequential networks from different patients to con-
struct an Integrated Sequential Network (ISN). Third, we infer TEDG from ISN by removing indirect 
associations with spectral techniques and minimal spanning tree algorithm. TEDG is the backbone of 
ISN, representing an optimal explanation of the mutation order across many patients (Figure 1B).
To test TEDG method and also to show how many patients are required to approximate the ground 
truth, we employ artificial examples by both simulating linear evolution and branching evolution of 
cancer, where the longitudinal data are generated by one-step Markov process and Nordling's multi-
mutation model (Nordling, 1953) (Figure 2A,B, ‘Materials and methods’). For example, in a cohort of 
15 patients with linear evolution, we start the Markov process of each case from no mutations at time 
zero. Mutation status at three time points 10, 20, and 30 are then successively updated based on the 
Markov chain transition probability described in ‘Materials and methods’. We finally pool all temporal 
information of those 15 patients to generate ISN (left panel of Figure 2D). The TEDG is further 
deduced by deconvoluting ISN. Suppose Gdir is the adjacent matrix of all direct interactions/orders, 
the observed ISN should be a summary of direct and indirect orders. The deconvolution is formulated 
by Gdir = Gobs(I + βGobs)−1, where, Gobs is the observed weighted adjacent matrix, I is the identify matrix, 
and β is the scaling factor between zero and one, indicating the degree of deconvolution. To evaluate 
TEDG, we define the accuracy by how frequently its results match the input model. To calculate the 
accuracy, we generate 10 simulated datasets of N patients (with three sequential samples per patient). 
In each simulation, we apply the TEDG analysis to reconstruct the sequential order and compare the 
result with the input model. We then apply the concept of accuracy to find a reasonable β for our sim-
ulation, by calculating the accuracy of TEDG with different β ∈ (0, 1) when N ∈ {1, 2, …, 100}. Figure 2C 
indicates that the optimal value of β is related to the number of samples, but the wide range of high 
accuracy region suggests that the TEDG results are robust to the parameter selection. With 30 patients, 
TEDG's accuracy for a linear model is 80%, and for a branching model, it reaches 90% (Figure 2E–G, 
‘Materials and methods’).
Tumor Evolutionary Directed Graph of CLL
In order to investigate the evolutionary history of CLL, we apply the TEDG framework to the driver 
genetic lesions of this leukemia. We study the most common alterations of 164 temporally sequential 
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Figure 1. Tumor Evolutionary Directed Graph (TEDG) framework. (A) A toy example of clonal evolution of one patient. The evolutionary history of four 
alterations A, B, C, and D is shown in the left panel. We then sample different time points and analyze genomic data. Specifically, for each patient, 
tagged-amplicon library next generation sequencing (NGS) and fluorescence in situ hybridization (FISH) analyses are carried out at different time points 
to evaluate the presence and quantify the clonal abundance of possible driver genetic lesions. Then we use mutation cell frequency (MCF) to adjust and 
unify the data (middle panel). Based on this longitudinal data, we build sequential network of one patient (right panel). CNA: copy number abnormali-
ties. (B) Sequential networks derived from different patients (left panel) are further pooled to generate Integrated Sequential Network (ISN), which is a 
cross-sectional integration of longitudinal data (middle panel). We then infer TEDG by removing the indirect interactions with network deconvolution 
and simplification algorithms (‘Materials and methods’). To construct TEDG, we calculate a minimal spanning tree-based on the deconvolution scores 
(right panel).
DOI: 10.7554/eLife.02869.003
The following figure supplements are available for figure 1:
Figure supplement 1. Adjustment of MAF based on copy number data. 
DOI: 10.7554/eLife.02869.004
Figure supplement 2. Relative timing of mutations of 70 CLL patients. 
DOI: 10.7554/eLife.02869.005
samples from 70 patients by high-depth next generation sequencing (NGS) and fluorescence in situ 
hybridization (FISH) analysis (‘Materials and methods’). Half (35 out of 70) of the patients have at least 
one subclonal genetic lesion with mutation frequency less than 20% at diagnosis (Figure 3—figure 
supplement 1). We firstly build sequential networks for each patient based on this longitudinal genetic 
data. Then, we pool all sequential networks to construct the ISN of CLL. We ask whether the genetic 
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Figure 2. The calibration of TEDG framework on the simulation of two basic evolutionary models. (A) The representation of linear model and branching 
model showing the sequential orders of four alterations. (B) The probability of observing different mutation profiles by Nordling's multi-mutation model. 
Specifically, if patient i harbored k0 mutations at time point t1, the probability to observe k more mutations at time point t2 is 
( )( )2 1– · –1– kf t te , where f 
represents the fitness of the new mutation. (C) The selection of parameter β. The color of heat map represents the accuracy of TEDG analysis, which is 
defined by the probability of TEDG reconstructing the input model. (D) An example showing the deconvolution algorithm on linear model. (F) An example 
showing the deconvolution algorithm on branching model. The left panel represents the ISNs of simulations of 15 patients. The weight of the edges 
represents the number of patients supporting the corresponding edges. The figures in the middle show the results of network deconvolution, where the 
numbers on the edge indicate deconvoluted weights. (E and G) The accuracy of TEDG framework on linear model and branching model at β = 0.2.
DOI: 10.7554/eLife.02869.006
lesions in CLL are temporally ordered or randomly accumulated and reason that if the genetic altera-
tions driving CLL progression follow a preferential order, there exists a well ordered directed flow in 
ISN. Figure 3A represents a hierarchical layout of ISN, which depicts an ordered structure of lesions 
in genes represented by sources (nodes with more outgoing arrows) and sinks (nodes with more 
incoming arrows) (p-value < 0.0001, chi square distribution).
To understand the evolutionary pattern of genetic alterations in CLL, we infer TEDG by removing 
indirect orders in ISN. The TEDG of CLL (Figure 3B) shows a clear pattern of the flow of alterations, 
revealing that genetic alterations of CLL are sequentially ordered in a branching mode. To statistically 
assess the temporal pattern of the genetic lesions, we use the binomial test to assess significance by 
assuming that the number of in-degree and out-degree of each alteration are randomly distributed. 
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Wang et al. eLife 2014;3:e02869. DOI: 10.7554/eLife.02869 6 of 23
Research article
BIRC3
TP53
delBIRC3
SF3B1
del11q
del17p
delRB1
NOTCH1
T12
del13q
MYD88
1
5
2
7
3
7
17
6
13
27
1
14
23
7
13
8
13
4
1
3
3
0
Outdegree Indegree
*
**
**
**
**
1 patient
2 patients
3 patients
4 patients
5 patients Late
EarlyA
2.9% 48.6%
88
del13q
+12
1
del 1
del17p
SF3B1
del11q
delBIRC3
TP53
BIRC3
Recurrence
Node size
Node color
B
TEDG of CLL
C
Figure 3. Evolutionary network analysis of CLL genetic lesions. (A) Network representing the sequential order of genomic alterations in CLL. The nodes 
in the network represent genetic alterations and the oriented edges (arrows) represent sequential events in different patients where alterations in one 
gene predate alterations in other genes. The size of the nodes represents the recurrence of alterations in our cohort. The thickness and the color codes 
of the edges represent the number of patients showing a specific connection between nodes. (B) TEDG of CLL, which is the deconvolution of ISN by 
removing indirect interactions, representing the optimal tree to explain observed orders in CLL patients. (C) The order of CLL alterations. We calculate 
both the sequential in-degree (number of arrows to a node) and out-degree (number of arrows from the node) of each genetic lesion in ISN and use the 
binomial test to assess the significance by assuming that the number of in-degree and out-degree is randomly distributed. Our null assumption is that if 
there is no preferential time ordering, there should be the same number of alterations in gene A occurring before alterations in gene B and vice versa, 
up to statistical fluctuations. Deviations from the null assumption indicate a preferential order in the development of the alterations. All events are sorted 
by fold change between out-degree and in-degree and all significant early or late events are labeled by *(p-value < 0.05) or **(p-value < 0.01).
DOI: 10.7554/eLife.02869.007
The following figure supplements are available for figure 3:
Figure supplement 1. Summary of longitudinal data in 70 patients. 
DOI: 10.7554/eLife.02869.008
Figure supplement 2. The order of CLL alterations with and without treatments. 
DOI: 10.7554/eLife.02869.009
Consistent with TEDG, this analysis suggests the following temporal order of the lesion: mutations of 
MYD88, deletion 13q14, +12, mutations of NOTCH1, RB1 deletion, 17p13 deletion, mutations of 
SF3B1, 11q22-q23 deletion, BIRC3 deletion, mutations of TP53, and mutations of BIRC3 (Figure 3C). 
Deletion of 13q14, +12 and mutations of NOTCH1 are significant early events in CLL development, 
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while mutations of TP53 and BIRC3 are significant late events. Though the sample size prevents statis-
tical considerations, MYD88 mutations might occur even before 13q14 deletion (one of six patients), 
indicating that activation of the Toll-like receptor pathway could be important in the initiation of a frac-
tion of CLL tumors (Arvaniti et al., 2011). The sequential order of the genetic lesions remains con-
sistent (Pearson's correlation = 0.9, p-value < 1e-3) when evolutionary networks are constructed with 
patients who received chemotherapy (Figure 3—figure supplement 2), suggesting that the order of 
development of the genetic lesions may be affected by therapy (the Pearson's correlation of the order 
in patients without chemotherapy is 0.4 with p-value > 0.1).
By considering each single type of mutation affecting the same gene as a distinct and independent 
node, we construct the comprehensive ISN of CLL mutations (Figure 4A). It is very difficult to capture 
useful information directly from ISN, while TEDG simplified the topology by capturing the backbone 
of tumor evolution (Figure 4B). We observe that the monoallelic 13q14 deletion, RB1 deletion, and 
+12 are significant early events (p-value < 0.01), while the BIRC3 E537fs and the TP53 R248Q are sig-
nificant late lesions (p-value < 0.05) (Figure 4—figure supplement 1). Also, the analysis of ISN and 
TEDG shows that different lesions affecting the same gene may occur in distinct branches and stages. 
For example, mutations K700E and K666E of SF3B1 are late events in cases harboring 13q14 deletion, 
while mutations R273C of TP53 are late events in cases with +12. Though the sample size prevents 
statistical considerations, TEDG reveals the H179R and Y234C missense substitutions in TP53 may be 
early events, while the R248Q, R273C, P152fs, and N239T substitutions are late events.
Based on pivotal NGS studies, two different evolutionary models have been proposed in CLL, 
namely gradual linear and branching evolution (Knight et al., 2012; Schuh et al., 2012). The analysis 
of our cohort (excluding patients with Richter's transformation, refer to ‘Materials and methods’ for 
details) shows that a minority of patients (n = 3/60, 5%; FDR = 0.1) are characterized by a significantly 
decreased or undetectable representation of the founding clone, coupled with a significant increase 
of a second subclone that represented a small subpopulation at an earlier time point, consistent with 
a branching evolution model (highlighted by yellow circle in Figure 5A–B, and Table 1). Interestingly, 
in all three cases clonal replacement events involve SF3B1 mutations and occur after treatment 
(Figure 5C), suggesting that the branching evolution model is closely connected to the combination 
of treatments and the emergence of SF3B1 mutations (p-value = 0.0016 by Fisher's exact test). This 
observation implies that, at the time of treatment requirement, limiting the knowledge of disease 
genetics to the dominant clone will likely be uninformative for accurate therapeutic decisions. Of par-
ticular interest in this scenario is the development of therapeutic strategies to prevent the branching 
evolution of the tumor, with the goal of eradicating dominant as well as minor clones (Anderson et al., 
2011; Notta et al., 2011; Ding et al., 2012; Egan et al., 2012; Keats et al., 2012; Walker et al., 
2012; Rossi et al., 2014).
Statistical association analysis of TEDG
To further investigate the relationship between driver genetic lesions in TEDG, we assess their associa-
tions and anti-associations in a cross-sectional cohort of 1403 CLL patients, of which 1054 cases are 
informative in at least one lesion (Figure 6A, Table 2). Most of the co-mutations (connected in red in 
Figure 6B) are experimentally confirmed by previous studies, including: co-occurrence of 17p13 dele-
tion and TP53 mutations, reflecting a typical two-hit model for tumor suppressor genes; co-occurrence 
of BIRC3 deletion, 11q22-q23 deletion, and BIRC3 mutations; and the relationship between NOTCH1 
mutations and +12 (Balatti et al., 2012; Del Giudice et al., 2012). In addition to previously reported 
associated lesions, this large cohort of patients allows the statistical power to reveal other significant 
and previously unreported co-occurrence interactions, including the co-occurrence of BIRC3 abnor-
malities with +12 and NOTCH1 mutations and the co-occurrence of 13q14 deletion and BIRC3 dele-
tion. This large cohort also reveals mutually exclusive relationships between +12 and 13q14 deletion 
and between NOTCH1 mutations and 13q14 deletion (connected in blue in Figure 6B). The statistical 
association analysis is consistent with the prediction of TEDG and indirectly validates the ability of 
TEDG in successfully capturing the major information in tumor evolution.
By integrating the topology of TEDG to the association analysis, two distinct and mutually exclusive 
evolutionary paths of CLL evolution are disclosed. The first evolutionary path involves CLL harboring 
+12 and NOTCH1 mutations as early driver events. In this path, clonal evolution proceeds toward 
the development of TP53 and BIRC3 abnormalities. The second evolutionary path involves 13q14 
deletion as early driver lesion and proceeds toward the development of SF3B1 mutations and BIRC3 
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Figure 4. TEDG analysis of specific genetic lesions. (A) Network representing the sequential order of specific genomic alterations. Two alterations are 
connected by a directed edge if they are observed to successively appear in at least one patient. The patient ID labels the corresponding edges, which 
are further colored by the number of patients. Nodes are colored by the fold change between out-degree and in-degree, indicating temporal order  
of corresponding alterations. The size of the nodes represents the recurrence of the alteration. (B) Tumor Evolutionary Directed Graph of 32 specific 
mutations. Some nodes and arrows in this figure are manually merged or adjusted for the purpose of illustration.
DOI: 10.7554/eLife.02869.010
Figure 4. Continued on next page
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abnormalities. Overall, our results are consistent with the different clinico-biological phenotype 
of +12 CLL and 13q14 deleted CLL and further support the hypothesis that at least two distinct 
genetic subtypes of CLL exist.
Rate of allele frequency change
We reason that if a subclone replaces the major clone during tumor evolution, it is because of its 
higher fitness. Although fitness of a clone is not directly measurable, the growth rate of mutation fre-
quency of drivers in this clone can serve as an indicator. Given this, mutations related to high fitness 
clones can be identified by extracting the alterations that rapidly change their allele/cell frequency 
within the tumor. We define the growth rate of each genetic lesion as the average increasing speed 
of mutation cell frequency per year (‘Materials and methods’). Interestingly, the growth rates of late 
events (17p13 deletion, mutations of SF3B1, 11q22-q23 deletion, BIRC3 deletion, mutations of TP53, 
and mutations of BIRC3) are found higher than those of early events (mutations of MYD88, 13q14 
deletion, +12, mutations of NOTCH1, and RB1 deletion) with p-value = 0.005 by Wilcoxon Rank-Sum 
Test (Figure 6C), revealing that late events may drive higher fitness or more aggressive clones. Note 
that the initiating lesions are usually clonal, presenting in most of the tumor cells, and therefore do not 
increase in frequency at the same magnitude as subclonal mutations. However, after eliminating clonal 
The following figure supplement is available for figure 4:
Figure supplement 1. Statistical test of in-degree and out-degree of specific alterations. 
DOI: 10.7554/eLife.02869.011
Figure 4. Continued
Figure 5. Fitting the evolution models. (A) Distribution of the clonal evolution pattern in the 60 non-Richter cases. Three of the 60 cases show replace-
ment during tumor progression. (B) Scatter plot showing p-values of observing increased and decreased subclones in the 80 samples of the 60 multi-
time point patients. Samples with evidence of clonal replacement are located in the right-up corner (highlighted by yellow circle). (C) Number of patients 
following linear vs branched evolution pattern according to SF3B1 mutational emergence and previous treatment (p-value 0.0016 by Fisher's exact test).
DOI: 10.7554/eLife.02869.012
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genetic lesions with MCF > 20% in the above analysis, we still find the growth rates of late and early 
events to be significantly different with p-value = 0.0114 by Wilcoxon Rank-Sum Test (Figure 6—
figure supplement 3).
We define maximal mutation frequency slope (MMFS) as the rate of allele frequency change of 
the fastest-growing clone in a patient (Table 3, ‘Materials and methods’). MMFS is a function that 
aims at characterizing the relative fitness of a particular clone carrying a particular mutation. In our 
cohort, only genetic lesions affecting the TP53 gene show a statistically significant association with 
MMFS (p-value = 0.0164, by Wilcoxon Rank-Sum Test). Clinically, the fastest-growing clones are 
strongly correlated with poor survival and Richter syndrome transformation, consistent with the fact 
that CLL transformed to Richter syndrome presents significantly higher MMFS values (p-value = 0.002, 
by Wilcoxon Rank-Sum Test) (Figure 6—figure supplement 1). Indeed, by survival analysis, having 
a clone with high MMFS associates with an approximately threefold significant increase in the hazard 
of death (HR: 3.17; 95% CI: 1.38–7.40; p-value = 0.005) and a significant shortening of overall sur-
vival (47% at 5 years) (Figure 6—figure supplement 2). Most deaths (77%) in patients carrying a clone 
with high MMFS are due to Richter syndrome transformation. Consistently, patients having a clone 
with high MMFS show an approximately fourfold increased risk of Richter syndrome development 
(HR: 4.61; 95% CI: 1.54–13.80; p-value = 0.003) and an ∼50% of them are projected to develop Richter 
syndrome at 5 years (Figure 6—figure supplement 2).
Discussion
It is not known whether there is a preferred order of mutations in the development of cancer and how 
the order of mutations may impact clinical outcomes. We propose a TEDG framework, which is able to 
integrate longitudinal and cross-sectional genomic data into a directed graph of tumor evolution. The 
flow in this graph reveals underlying paths of tumor progression. Starting from time-series genomic 
data in one patient, a sequential network is reconstructed to capture the possible historical events of 
Table 1. Patients with branching evolution*
Patient ID
Sampling  
time Treatment
Increased  
alterations
Decreased 
alterations
Detectable 
alterations
#1 2001 None – – SF3B1 (K666E), SF3B1 
(K700E), del13q
2005 FC SF3B1 (K666E) None SF3B1 (K666E), SF3B1 
(K700E), del13q
2008 FCR/CAM/RBEN SF3B1 (K700E), del11q None SF3B1 (K666E), SF3B1 
(K700E), del13q, 
del11q
2011 BENCAM SF3B1 (K700E), del11q, 
del13q, delBIRC3
SF3B1  
(K666E)
SF3B1 (K700E), 
del13q, del11q, 
delBIRC3
#14 2004 RF – – +12, del13q
2007 FC/CAM None None +12, del13q
2010 BENCAM TP53 (R248Q), del17p, 
SF3B1 (K666E)
None +12, del13q, TP53 
(R248Q), del17p, 
SF3B1 (K666E)
2012 BENDOFA TP53 (R248Q), del17p, 
SF3B1 (K666E), T12
del13q +12, del13q, TP53 
(R248Q), del17p, 
SF3B1 (K666E)
#33 2002 None – – NOTCH1 (P2514-)
2004 FCR SF3B1 (K700E) None NOTCH1 (P2514-), 
SF3B1 (K700E)
2009 FCR SF3B1 (K700E) NOTCH1  
(P2514-)
SF3B1 (K700E)
*FC, fludarabine, cyclophosphamide; FCR, fludarabine, cyclophosphamide, rituximab; CAM, Campath; RBEN, 
rituximab, bendamustine; BENCAM, bendamustine, Campath; RF, rituximab, fludarabine; BENDOFA, 
bendamustine, ofatumumab.
DOI: 10.7554/eLife.02869.013
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Figure 6. Association network of CLL lesions in a larger cohort. (A) The mutation status of 1054 CLL patients, which is informative in 11 most common 
genetic lesions in this leukemia. (B) The association analysis of CLL genetic lesions in TEDG. Lesion pairs are connected if they are significantly co-mutated 
(red) or mutually exclusive (blue). (C) Box plot of growth rate of all genetic lesions.
DOI: 10.7554/eLife.02869.014
The following figure supplements are available for figure 6:
Figure supplement 1. Box plot to show the difference of Richter and non-Richter, and mutations of TP53 in Maximal Mutation Frequency Slope. 
DOI: 10.7554/eLife.02869.015
Figure supplement 2. Survival analysis of fittest genomic alterations. 
DOI: 10.7554/eLife.02869.016
Figure supplement 3. Comparison of the growth rates of subclonal alterations between early and late events. 
DOI: 10.7554/eLife.02869.017
the evolution in the particular tumor. Integrating sequential data from many patients, we collect the 
ensemble of tumor histories by ISN, which presents a comprehensive topology of evolutionary land-
scape. A recent technology of network deconvolution is able to distinguish direct and indirect inter-
actions using spectral methods, which reduce the weights of indirect connections and remove low 
weighted edges by selecting appropriate cut-offs (Feizi et al., 2013). To adapt this method to our 
particular problem depending on the number of samples, we introduce a degree parameter, β. To gain 
insights of the selection of beta, we propose a strategy to simulate tumor evolution by a one-step 
Markov process, with transition probability derived from Nordling's multi-mutation model. A linear 
and a branching evolution model are separately simulated in a study of four alterations. The proof-of-
concept simulation shows that the TEDG strategy can obtain excellent performance in capturing the 
evolutionary history when the number of cases is beyond 30.
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Table 2. Clinical features at presentation of the CLL cohorts*
TEDG analysis SA analysis
N Total % N Total %
IGHV homology >98% 37 69 53.6 532 1380 38.6
del13q14 35 70 50.0 682 1403 48.6
+12 19 70 27.1 205 1403 14.6
del11q22-q23 8 70 11.4 136 1403 9.7
del17p13 20 70 28.6 114 1403 8.1
TP53 mutation 22 70 31.4 114 1401 8.1
NOTCH1 mutation 22 70 31.4 150 1403 10.7
SF3B1 mutation 17 70 24.3 100 1403 7.1
MYD88 mutation 6 70 8.6 52 1403 3.7
BIRC3 mutation 10 70 14.3 41 1403 2.9
BIRC3 deletion 6 70 8.6 79 1403 5.6
*TEDG analysis, Tumor Evolutionary Directed Graphs analysis; SA analysis, Statistical Association analysis; IGHV, 
immunoglobulin heavy variable gene; FISH, fluorescence in situ hybridization.
DOI: 10.7554/eLife.02869.018
We apply TEDG to CLL and: (i) reconstruct an evolutionary network representing the sequential 
order of genetic lesions occurring during the course of this disease; (ii) investigate statistical associa-
tions and competitiveness of driver genetic lesions to uncover evolutionary paths; and (iii) correlate 
the order of alterations with the kinetics of changes in their allelic abundance, to identify the molecular 
alterations associated with the fastest growth of a subclone and their clinical impact on outcome.
Phylogenetic trees are often employed to infer temporal order of gene mutations by assuming that 
common ancestors are early events, but phylogenetic methods usually require higher number of alter-
ations than the ones available in our cohort. Standard statistical techniques to assess the significance of 
different branches rely on bootstrapping segregating sites, and the statistical power of these techniques 
using longitudinal data from cancer patients in few selected driver genes is extremely limited. None of 
the standard phylogenetic methods such as distance matrix methods, Bayesian phylogenetic methods, 
or parsimony methods can produce branches with enough bootstrap support (>80%). On the other hand, 
TEDG works with aggregate data from several patients allowing statistical power for robust estimates.
According to TEDG analysis, the molecular lesions of CLL are temporally ordered in a specific fash-
ion rather than being randomly accumulated. Among recurrent lesions, 13q14 deletion and +12 are 
initiating events, while mutations of TP53 and BIRC3 are late. This observation is consistent with the 
notion that del13q and +12 occur at a similar prevalence in all CLL phases, including monoclonal B-cell 
lymphocytosis, a condition that often anticipates overt CLL, thus suggesting that they are early events 
(Rawstron et al., 2008; Nieto et al., 2009; Rossi et al., 2009b; Fazi et al., 2011; Pasqualucci et al., 
2011; Kern et al., 2012). Also, 13q14 deletion has been directly implicated in CLL initiation (Klein 
et al., 2010). On the other hand, late-onset abnormalities are known to accumulate in more advanced 
phases of the disease, thus suggesting that they are second-hit lesions (Zenz et al., 2009; Rossi et al., 
2012). In our model, mutations of SF3B1 and 11q22-q23 deletions appear to be acquired at an inter-
mediate time point. This observation is consistent with the clinical observation that mutations of SF3B1 
and 11q22-q23 deletion co-segregate with an intermediate prognostic group of CLL (Döhner et al., 
2000; Oscier et al., 2013; Rossi et al., 2014).
By integrating the cross-sectional data of association and anti-association between genetic lesions 
at CLL diagnosis with longitudinal data of clonal evolution from TEDG, two distinct and mutually exclu-
sive evolutionary paths of evolution emerge. The first evolutionary path involves CLL initially harboring 
+12 and NOTCH1 mutations. In this path, clonal evolution proceeds toward the development of TP53 
and BIRC3 abnormalities. The second evolutionary path involves CLL initially harboring 13q14 deletion 
and proceeds toward the development of SF3B1 mutations and BIRC3 abnormalities. Our data, as well 
as previous analyses (Rossi et al., 2013), show that deletion of 13q14 and +12 are mutually exclusive 
in CLL. From a clinical standpoint, +12 CLL is known to stand out of typical 13q14 deleted CLL because 
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of their atypical cytomorphology and phenotype, the more intense expression of CD20, the preferen-
tial nodal presentation and the higher risk of transformation to Richter syndrome. These notions along 
with our novel observation that +12 and 13q14 deleted CLL proceed through distinct paths of clonal 
evolutions further support the hypothesis that at least two distinct genetic subtypes of CLL exist.
The presence at diagnosis of fully clonal genetic lesions that are considered late genetic events 
in CLL evolution, such as TP53 abnormalities, is already known to have an adverse impact on disease 
outcome (Zenz et al., 2008, 2010; Dicker et al., 2009; Malcikova et al., 2009; Rossi et al., 2009a; 
Gonzalez et al., 2011). We observe that a fraction of TP53 abnormalities, though subclonal at presen-
tation, lead to expansion of fitter subclones that progressively predominate with time in the tumor 
architecture. The clinical impact of this observation is supported by the evidence that harboring higher 
fitness alterations correlates with poor survival and increased risk of CLL transformation into an aggres-
sive lymphoma, an often-lethal complication known as Richter syndrome.
In this study, we have considered some of the most important and clinically relevant drivers of CLL 
(Rossi et al., 2013). The ATM mutations are also commonly found in CLL; however, the ATM gene is 
large and highly polymorphic without well-known hotspots. Therefore, the distinction of its driver 
mutations from constitutional variants is challenging. Also, from a clinical standpoint, the prognostic 
relevance of ATM mutations in CLL is still controversial, so we have excluded this gene from the current 
study (Lozanski et al., 2012; Ouillette et al., 2012; Skowronska et al., 2012).
In conclusion, the application of TEDG to CLL provides the proof-of-principle that this method 
is able to: (i) improve cancer classification and dissection into genetic subgroups following different 
paths of clonal evolution; and (ii) anticipate the genetic composition of the progressive/relapsed 
Table 3. Patients showing high maximal mutation frequency slope (MMFS)
Patient MMFS*
Fast growing  
mutations MCF1 (%) MCF2 (%)
dT  
(moths) Treatment
Richter 
syndrome 
transformation
#52 117.7 TP53 (P152+) 2.1 11.4 <1 None Yes
#68 9.1 TP53 (R273C) 0.0 100.0 11 None No
#51 6.7 SF3B1 (I704F) 12.2 68.9 5 RCVP Yes
#37 6.4 TP53 (R248Q) 3.8 90.0 10 RDHAOX Yes
#57 5.9 NOTCH1 (P2514-) 0.8 94.2 12 None Yes
#47 4.6 del13q 37.6 100.0 13 None No
#14 3.9 del17p 18.9 90.0 16 A No
#42 3.4 TP53 (N239T) 0.0 100.0 16 RDHAOX Yes
#4 3.3 del17p 53.6 100.0 15 CLB-O No
#54 3.0 NOTCH1 (P2415-) 100.0† 100.0 22 FCO No
#22 2.9 BIRC3 deletion 0.0 93.9 29 FCR No
#20 2.8 del13q 0.0 100.0 36 CLB No
#63 2.5 BIRC3 (M388V) 0.0 86.0 24 FCR Yes
#6 2.3 del17p 0.0 92.1 34 CLB No
#38 2.3 NOTCH1 (P2514-) 41.7 42.9 4 CVP Yes
#13 2.2 TP53 (G136H) 0.0 100.0 45 RDHAOX No
#1 2.1 del11q 11.8 100.0 41 FCR/A/BR No
*MMFS, maximal mutation frequency slope (in standard deviation per year); MCF1, mutation cell frequency of 
selected mutation at the first time point; MCF2, mutation cell frequency at the second time point; dT, the elapsed 
time between two samples; RCVP, rituximab, cyclophosphamide, vincristine, prednisone; RDHAOX, rituximab, 
dexamethasone, high dose cytarabine, oxaliplatin; A, alemtuzumab; CLB-O, chlorambucil, ofatumumab; FCO, 
fludarabine, cyclophosphamide, ofatumumab; FCR, fludarabine, cyclophosphamide, rituximab; CLB, chlorambucil; 
CVP, rituximab, cyclophosphamide, vincristine, prednisone; BR, bendamustine, rituximab.
†Total number of the cancer cells with NOTCH1 alteration does not change, but the allele frequency of the 
mutation increases because of the deletion of the wild-type allele.
DOI: 10.7554/eLife.02869.019
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disease according to the genetic composition of the tumor clone at the time of diagnosis, including 
the development of genetic lesions associated with chemorefractoriness. TEDG provides a general 
framework that could be used to study and compare the evolutionary histories of other tumors.
Materials and methods
Samples
We collected 202 CLL patients provided with at least 2 sequential samples and followed for at least 
2 years after presentation (median interval between baseline and last sequential sample: 62.8 months, 
range 24–150 months). 70 out of the 202 patients were informative for TP53, NOTCH1, SF3B1, MYD88, 
or BIRC3 mutations (which are the most common mutations in this leukemia), overall accounting for 
164 paired sequential samples collected at diagnosis, progression, and last follow-up. To analyze the 
dynamics of those mutations, we carried out high-depth next generation sequencing (NGS) to quantify 
the mutation allele frequencies at each time point of the disease course and to establish their modifi-
cations during leukemia progression. Additionally, copy number abnormalities at 13q14, chromosome 
12, 11q22-q23, 17p13, as well as at the RB1, and BIRC3 loci were investigated by FISH. Inclusion cri-
teria for the longitudinal analysis of clonal evolution were: (i) having at least two years of follow-up 
after diagnosis; and (ii) availability of >2 sequential samples collected at: (a) diagnosis; (b) each pro-
gression requiring treatment; (c) last follow-up. CLL diagnosis was according to 2008 IWCLL-NCI 
criteria and confirmed by a flow cytometry score >3 in all cases. Monoclonal B-cell lymphocytosis 
(MBL) was excluded. The study was approved by the institutional ethical committee of the Azienda 
Ospedaliero-Universitaria Maggiore della Carità di Novara affiliated with the Amedeo Avogadro 
University of Eastern Piedmont, Novara, Italy (Protocol Code 59/CE; Study Number CE 8/11). Patients 
provided informed consent in accordance with local IRB requirements and Declaration of Helsinki.
CLL samples were extracted from fresh or frozen peripheral blood mononuclear cells (PBMC) iso-
lated by Ficoll-Paque gradient centrifugation. In all cases, the fraction of tumor cells corresponded to 
70–98% as assessed by flow cytometry. Matched normal DNA from the same patient was obtained 
from saliva or from purified granulocytes and confirmed to be tumor-free by PCR of tumor-specific 
IGHV-D-J rearrangements. High-molecular-weight (HMW) genomic DNA was extracted from tumor 
and normal samples according to standard procedures. DNA was quantified by the NanoDrop 2000C 
spectrophotometer (Thermo Scientific, Wilmington, DE). To validate TEDG, 1403 newly diagnosed 
and previously untreated CLL were enrolled in the study, of whom 931 (66%) were provided with clin-
ical data and regular follow-up (Table 2). The frequency of alterations was higher in TEDG analysis 
group, because only informative patients with known mutated driver genes were included. Cross-
sectional investigation of the associations and anti-associations between the most recurrent genetic 
lesions at diagnosis was based on the entire CLL cohort of 1403 patients. Survival analysis was based 
on CLL cases provided with clinical data (n = 931). Mutation screening of the IGHV, TP53, NOTCH1, 
SF3B1, MYD88, and BIRC3 genes were performed by Sanger sequencing.
Estimation of the variant allele frequency
Among cases that were informative for TP53, NOTCH1, SF3B1, MYD88, or BIRC3 mutations at any 
time point in the disease course, we carried out high-depth NGS to quantify the variant allele frequen-
cies at each stage of their disease. Positions known to harbor TP53, NOTCH1, SF3B1, MYD88, or 
BIRC3 mutations by Sanger sequencing were amplified from genomic DNA by oligonucleotides con-
taining the gene-specific sequences, along with 10-bp MID tag for multiplexing and amplicon library 
A and B sequencing adapters. The obtained amplicon library was subjected to deep sequencing on 
the Genome Sequencer Junior instrument (454 Life Sciences). In order to obtain at least 700-fold cov-
erage per amplicon, no more than 100 amplicons/run were analyzed. The obtained sequencing reads 
were mapped to reference sequences and analyzed by the Amplicon Variant Analyzer software (Roche) 
to establish the mutant allele frequency. The sequencing depth in this study is on average 1200×, 
which is sufficient for a highly sensitive detection of mutations with allele frequency >1% out of the 
background error noise (Rossi et al., 2014).
Fluorescence in situ hybridization (FISH)
Probes used for FISH analysis were: (i) LSID13S319 (13q14 deletion), CEP12 (trisomy 12), LSIp53 
(17p13/TP53 deletion), and LSIATM (11q2-q23/ATM deletion) (Abbott, Rome, Italy); and (ii) the 
RP11-177O8 (BIRC3) BAC clone. The labeled BIRC3 BAC probe was tested against normal control 
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metaphases to verify the specificity of the hybridization. For each probe, at least 400 interphase cells 
with well-delineated fluorescent spots were examined. Nuclei were counterstained with 4′,6′-diamid-
ino-2-phenylindole (DAPI) and antifade reagent, and signals were visualized using an Olympus BX51 
microscope (Olympus Italia, Milan, Italy).
Fluorescence-activated cell sorting (FACS) analysis
The count of CD19+CD5+ cells is a standard assay to define the representation of CLL cells in a diagnostic 
or research sample as measured by Fluorescence-activated cell sorting (FACS) analysis. A FACSCalibur 
flow cytometer (Becton–Dickinson) was utilized for the analysis. Expression of CD5 and CD19 was 
analyzed by combining Peridinin-Chlorophyll-Protein–Cyanine-5.5 (PerCP–Cy5.5)-conjugated anti-CD19 
mAbs and fluorescein isothiocyanate-conjugated anti-CD5 mAbs. In order to estimate the proportion 
of cells co-expressing CD19 and CD5, for each sample events were acquired by gating on low forward 
and side scatter (FSC/SSC) CD19+ cells, which were further divided into CD5− and CD5+ subsets. 
Irrelevant isotype-matched antibodies (Becton–Dickinson) were used to determine background fluo-
rescence. FACS data of all samples are listed in Supplementary file 2.
Adjustment of mutation frequency
To consider tumor content, we performed CD19/CD5 FACS analysis to quantify the fraction of tumor 
cells. To unify FISH and NGS data, and also to adjust MAF of mutations in genes with copy number 
abnormalities, we introduced mutation cell frequency (MCF). As shown in Figure 1—figure supple-
ment 1A, MCF represents the fraction of cancer cells containing particular alterations. Unlike MAF, 
copy numbers or tumor content do not affect MCF of a point mutation. For instance, if tumor purity 
is 70% and MAF of a heterogeneous variance in a diploid region is 0.2, then MCF is approximated 
by 0.2 × 2/0.7 ≈ 0.57. To infer MCF of different types of lesions, we applied the following strategy:
 
i. MCF of a copy number abnormality (i.e., T12, del11q, del13q_x1, del13q_x2, del17p, delBIRC3, 
delRB1_x1, delRB1_x2) was calculated by FISH analysis divided by the fraction of CD19/CD5 cells 
based on FACS, correcting for the tumor purity.
ii. Genes whose copy numbers were not frequently changed, such as MYD88 and SF3B1, were 
considered as diploid. So the MCF should be close to twofolds of MAF. However, MAF of some 
mutations might exceed 0.5, because of the random noise introduced in PCR. Here, MCF could be 
simply defined as a Piecewise function:
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smooth this function, a Hill function was introduced, assuming
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where K and n are parameters. To find optimal parameters, such that MCF ≈ 2 × MAF, we optimize the 
following objective function:
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A grid-search method was applied to exhaust potential values of K and n. Particularly, for K ∈ {20,⋯, 29} 
and n ∈ {1,⋯, 10}, F was calculated by the numerical integration of the above equation. Figure 1—
figure supplement 1B shows that the optimal solution is ˆ =16K  and ˆ =2n . So for mutations of MYD88 
and SF3B1,
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This Hill function, which was used to smooth the piecewise function, showed a more smooth corre-
lation between MAF and MCF (Figure 1—figure supplement 1C). Additionally, by comparing FACS 
measurement of tumor purity, this Hill function form of MCF is more robust than either MAF without 
adjustment or simplistic piecewise function in assessing the fraction of cancer nuclei (Figure 1—figure 
supplement 1E).
 
iii. Genes that are frequently deleted in CLL, such as TP53 and BIRC3, were analyzed in the model 
without considering copy-neutral LOH or homozygous deletions (Figure 1—figure supplement 1D). 
We assume four different cell types: wild type (upper left), heterozygous deletion (upper right), 
mutation (lower left), and both mutation and deletion (lower right). The cell fractions were repre-
sented by xi(i = 1,⋯, 4), respectively. So 
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Here if we use Kˆ  and nˆ to represent the optimal solution given MCFdel, for mutations of TP53 and BIRC3,
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The MCF values were then divided by the fraction of CD19+CD5+ cells based on FACS.
Simulation of linear and branching cancer models
To generate the artificial data for TEDG, we simulate cancer clonal evolution as a one-step Markov 
process, that is, the transition probability of mutation profile ( ) ( )⋯
–1 1 –1
| , , = |
k k k kt t t t t
P Pψ ψ ψ ψ ψ , where 
ψtk is the observed mutation profile at time tk, which depended on the mutation profile at time tk−1. To 
define the transition probability, we focused on two simple models of four mutations x1,x2,x3,x4.
In the linear evolution model, we assumed that all mutations were mutated in a linear order shown 
in the left panel of Figure 2A. All possibilities of mutation status are
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According to Nordling's multi-mutation model (Nordling, 1953), the transition probability was 
defined as
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where f represents fitness of the new mutation. The transition probability is shown in Figure 2B. The 
longitudinal data were then generated for each patient following the above model. To simplify the 
model, we fixed the number of time points (three) and the length of interval between time points 
(ten). We asked whether or not TEDG framework can reconstruct the order of mutations and how 
many patients are required. To answer this question, we applied a grid-search strategy to optimize 
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parameter β and number of patients. Specifically, all possible combinations of parameter β from 0 to 
1 (step by 0.1) and patient number from 1 to 100 (step by 1) are exhausted. For each combination, we 
randomly simulated the cancer patients and applied TEDG framework to reconstruct the order for 10 
times. The frequency of reconstructing the exact order was defined as the accuracy of TEDG. Figure 2D 
shows an example with β equals 0.2 and the number of patients equals 15. Edge weights of ISN pre-
sent the number of simulated patients with one mutation happening before another. The techniques of 
deconvolution and minimal spanning tree reconstruct the real structure by removing indirect interactions. 
Figure 2E summarizes the correlation between number of patients and optimal accuracy of TEDG.
Different from linear model, the branching model assumes that x3 and x4 are independently fol-
lowing the mutation of x2. All possibilities of mutation status are
( ) ( ) ( ) ( ){ }0 1 1 2 1 2 3 1 2 3 4 1 2 4= , = , = , , = , , , = , ,  .x x x x x x x x xπ φ π π π π  
According to Nordling's multi-mutation model (Nordling, 1953), when j ≤ 2, the transition proba-
bility is the same as linear model:
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When j > 2, the transition probability is
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Figure 2F shows an example of branching model with β equals 0.2 and number of patient equals 
15. Figure 2G summarized the correlation between number of patients and optimal accuracy of TEDG 
in branching model.
Network construction and analysis
To construct the sequential network of alterations for each tumor, we monitored the presence or 
absence of each genetic lesion in each sample. By collecting the clonal representation of each lesion 
from NGS and FISH analysis, we defined the status of each lesion with a cut-off of 5%. If the frequency 
of a genetic lesion is larger than 5%, we will name it as present; otherwise absent. If event A predates 
event B, we added a directed link between A and B. The ISN was constructed by pooling all sequential 
networks from different patients. To simplify ISN, we removed self-loops by subtracting the weight of 
weaker direction. To hierarchically layout the simplified ISN, we use yFiles Hierarchical Layout algo-
rithm in Cytoscape 2.8.2, which well represents main direction or ‘flow’ in a directed network. With this 
method, nodes were placed in hierarchically arranged layers and the nodes within each layer are 
ordered in such a way that minimizes the number of edge crossings (Smoot et al., 2011). To statisti-
cally test whether the alterations are temporally ordered or randomly accumulated, we assume that 
in-degree (the number of incoming arrows) i
in
d  is equal to out-degree (the number of outgoing arrows) 
i
out
d  for each node i, and then 
( )2–  
 
i i
in out
i
i out
d d
d
∑  follows a chi square distribution with degree of freedom 
n − 1, where n is the number nodes in the network. To test the statistical association of lesions in 
TEDG, we counted the number of samples carrying each pair of lesions and then calculated the p-value 
based on hypergeometric distribution to test whether the two genetic lesions are independent or not. 
To consider the effect of multi-hypothesizes, we corrected p-values with Bonferroni method and made 
a cut-off of 0.05. If two lesions were significantly co-mutated, a red link was added, while if they were 
significantly mutually exclusive, a blue edge was added.
Suppose Gdir is the adjacent matrix of all direct interactions/orders, the simplified ISN should be 
a summary of direct and indirect orders in the deconvolution formula Gdir = Gobs(I + βGobs)−1, where, 
Genomics and evolutionary biology | Human biology and medicine
Wang et al. eLife 2014;3:e02869. DOI: 10.7554/eLife.02869 18 of 23
Research article
Gobs is the observed weighted adjacent matrix, I is the identify matrix, and β is a scaling factor between 
zero and one indicating the degree of deconvolution. The resulting matrix of deconvolution for-
mula indicates the score of an edge to be a direct interaction (edge weights in the middle panel of 
Figure 2D,F). We then introduced a minimal spanning tree-based method to determine the final 
TEDG, in which we transformed the deconvoluted weights with a negative exponential function, and 
then calculated the minimal spanning tree with Prim's algorithm.
Fitting the evolutionary models
We developed Fit the Evolutionary Model (FEM) to properly fit the evolutionary model by sys-
tematically identifying clonal replacement in all sample pairs. FEM defines Z-scores for variant 
allele frequency by NGS and percentage of nuclei harboring abnormalities by FISH to represent 
normalized changes of the frequency of the lesions. For ith mutation in jth patient at the kth time 
point tk
( ) ( ) ( )
( ) ( ) ( ) ( )     
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where f is the mutation frequency of some particular gene mutation and σseq is its standard variation. 
Similarly, for the ith copy number change in the jth patient at the kth time point tk
( ) ( ) ( )
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where f is the frequency nuclei harboring the abnormality of some particular gene mutation and σFISH 
is its standard variation.
The change of genetic lesion frequency is a synergic effect of treatment, tumor progression, and 
experimental noises, such as sequencing error or change of tumor purity. To obtain the variance caused 
by background noises, FEM robustly fit σseq and σFISH by eliminating data obviously affected by treat-
ments or tumor progression. Based on this, we could calculate p-values of each genetic lesion in all 
sample pairs. To assess whether there was a significantly increased (or decreased) subclone in a given 
sample pair, we use Fisher's combinational test to combine p-values of all increased (or decreased) 
genetic lesions. The resulting p-values were separately defined as P_increase and P_decrease. Sample 
pairs that were significant in both P_increase and P_decrease were defined as sample pairs containing 
replacement events, which were further fit to the branching evolution model. All the others were com-
patible with the gradual linear model.
Growth rate and maximal mutation frequency slope (MMFS)
To investigate the fitness of genetic lesions, we defined growth rate and the maximal mutation fre-
quency slope (MMFS). For the ith mutation in the jth patient at the kth time point tk, mutation fre-
quency slope is defined as ( ) ( )
−
=
−
1
j
i kj
i k
k k
z t
s t
t t
, where z is the Z-scores defined above. The growth rate of 
ith mutation in the jth patient at the kth time point tk is defined as ( ) ( ){ }= ,0j ji k i kg t max s t . Furthermore, 
for the jth patient, MMFS is defined as ( ){ }   =j ji k i ks max max s t .
Survival analysis
Overall survival (OS) was measured from date of initial presentation to date of death from any cause 
(event) or last follow-up (censoring). The cumulative probability of Richter syndrome transformation 
was measured from date of initial presentation to date of the biopsy documenting Richter syndrome 
transformation (event), death or last follow-up (censoring). Survival analysis was performed by the 
Kaplan–Meier method. The crude association between time-fixed exposure variables at diagnosis and 
survival was estimated by Cox proportional hazard regression. The analysis was performed with the 
Statistical Package for the Social Sciences (SPSS) software v.20.0 (Chicago, IL).
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Candidate gene mutation screening
The mutation hotspots of TP53 (exons 4–9, including splicing sites; RefSeq NM_000546.5), NOTCH1 
(exon 34, including splicing sites; RefSeq NM_017617.2), SF3B1 (exons 14, 15, 16, 18, including splice 
sites; RefSeq NM_012433.2), MYD88 (exons 3, 5, including splicing sites; RefSeq NM_002468.4), and 
BIRC3 (exons 6–9, including splicing sites; RefSeq NM_001165.4) genes were analyzed by PCR ampli-
fication and DNA direct sequencing of high-molecular weight genomic DNA. Sequences for all anno-
tated exons and flanking splice sites were retrieved from the UCSC Human Genome database using 
the corresponding mRNA accession number as a reference. PCR primers, located ∼50 bp upstream or 
downstream to target exon boundaries, were either derived from previously published studies or 
designed in the Primer 3 program (http://frodo.wi.mit.edu/primer3/) and filtered using UCSC in silico 
PCR to exclude pairs yielding more than a single product. All PCR primers and conditions are listed in 
Supplementary file 1. Purified amplicons were subjected to conventional DNA Sanger sequencing 
using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems) and compared to the corresponding 
germline sequences using the Mutation Surveyor Version 4.0.5 software package (SoftGenetics) after 
automated and/or manual curation. Of the evaluated sequences, 99% had a Phred score of 20 or more 
and 97% had a score of 30 or more. Candidate variants were confirmed from both strands on inde-
pendent PCR products. The following databases were used to exclude known germline variants: 
Human dbSNP Database at NCBI (Build 136) (http://www.ncbi.nlm.nih.gov/snp); Ensembl Database 
(http://www.ensembl.org/index.html); The 1000 Genomes Project (http://www.1000genomes.org/); 
five single-genome projects available at the UCSC Genome Bioinformatics resource (http://genome.
ucsc.edu/). Synonymous variants, previously reported germline polymorphisms and changes present 
in the matched normal DNA were removed from the analysis.
IGHV-IGHD-IGHJ rearrangement analysis
PCR amplification of IGHV-IGHD-IGHJ rearrangements was performed on high molecular weight 
genomic DNA using IGHV leader primers or consensus primers for the IGHV FR1 along with appro-
priate IGHJ genes, as previously described. PCR products were directly sequenced with the ABI 
PRISM BigDye Terminator v1.1 Ready Reaction Cycle Sequencing kit (Applied Biosystems) using 
the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). Sequences were analyzed using the 
IMGT databases and the IMGT/V-QUEST tool (version 3.2.17, Université Montpellier 2, CNRS, 
LIGM, Montpellier, France).
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